Publicacións nas que colabora con Ovidio Fernández Calvo (13)

2024

  1. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology

  2. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

  3. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

  4. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

2022

  1. Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

    Clinical and Translational Oncology, Vol. 24, Núm. 8, pp. 1515-1523

2018

  1. Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?

    Actas Urologicas Espanolas

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

2016

  1. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

    Current Oncology Reports, Vol. 18, Núm. 12

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology

2011

  1. Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

    Cancer Genomics and Proteomics, Vol. 8, Núm. 2, pp. 93-101

  2. Molecular basis of hypertension side effects induced by sunitinib

    Anti-Cancer Drugs, Vol. 22, Núm. 1, pp. 1-8